Overview

A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients

Status:
Not yet recruiting

Trial end date:
2023-07-31

Target enrollment:

Participant gender:

Summary

The study is being conducted to evaluate safety, tolerability and preliminary efficacy of Camrelizumab for Injection in combination with Famitinib malate capsule and Paclitaxel For Injection(Albumin Bound) for advanced solid tumors of patients. To explore the reasonable dosage of dosage regimen of combination therapy for advanced malignant tumors of patients.

Phase:

Phase 2

Details

Lead Sponsor:

Jiangsu HengRui Medicine Co., Ltd.

Treatments:

Paclitaxel